Reviewing Cerus Corporation (CERS) and Stryker Corporation (SYK)
Cerus Corporation (NASDAQ: CERS) and Stryker Corporation (NYSE:SYK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Cerus Corporation does not pay a dividend. Stryker Corporation pays out 37.9% of its earnings in the form of a dividend. Stryker Corporation has raised its dividend for 6 consecutive years.
Insider and Institutional Ownership
58.7% of Cerus Corporation shares are owned by institutional investors. Comparatively, 74.2% of Stryker Corporation shares are owned by institutional investors. 7.4% of Cerus Corporation shares are owned by company insiders. Comparatively, 7.4% of Stryker Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Cerus Corporation and Stryker Corporation’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cerus Corporation||$36.83 million||7.97||-$61.75 million||($0.61)||-4.41|
|Stryker Corporation||$11.96 billion||4.45||$3.29 billion||$4.48||31.75|
Stryker Corporation has higher revenue and earnings than Cerus Corporation. Cerus Corporation is trading at a lower price-to-earnings ratio than Stryker Corporation, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Cerus Corporation and Stryker Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus Corporation presently has a consensus price target of $7.25, suggesting a potential upside of 169.52%. Stryker Corporation has a consensus price target of $145.31, suggesting a potential upside of 2.17%. Given Cerus Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus Corporation is more favorable than Stryker Corporation.
This table compares Cerus Corporation and Stryker Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Cerus Corporation has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Stryker Corporation has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
Stryker Corporation beats Cerus Corporation on 10 of the 15 factors compared between the two stocks.
About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Receive News & Stock Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related stocks with our FREE daily email newsletter.